$100.28
4.19% day before yesterday
Nasdaq, Jan 02, 10:04 pm CET
ISIN
US7207951036
Symbol
PVLA

Pieris Pharmaceuticals, Inc. Stock price

$100.28
+8.69 9.49% 1M
+76.46 320.90% 6M
-4.39 4.19% YTD
+88.28 735.67% 1Y
+17.08 20.53% 3Y
-118.12 54.08% 5Y
-82.92 45.26% 10Y
-119.72 54.42% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-4.39 4.19%
ISIN
US7207951036
Symbol
PVLA
Industry

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$1.1b
Net debt
positive
Cash
$63.6m
Shares outstanding
11.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
30.4
Financial Health
Equity Ratio
71.6%
Return on Equity
-27.0%
ROCE
-50.2%
ROIC
861.5%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-38.8m
EBIT
$-28.6m | $-38.9m
Net Income
$-34.7m | $-39.3m
Free Cash Flow
$-22.7m
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
- | -
EBIT
-42.8% | -177.7%
Net Income
-73.3% | -131.1%
Free Cash Flow
19.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.2
FCF per Share
$-2.1
Short interest
8.4%
Employees
-
Rev per Employee
-
Show more

Is Pieris Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Pieris Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:

Buy
94%
Hold
6%

Financial data from Pieris Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.38 6.38
46% 46%
-
- Research and Development Expense 22 22
235% 235%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -29 -29
43% 43%
-
Net Profit -35 -35
73% 73%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pieris Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pieris Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
11 days ago
Palvella Therapeutics offers a compelling risk/reward profile, underpinned by strong Phase 2 data and a pivotal Phase 3 catalyst in Q1 2026. Palvella's QTORIN rapamycin platform demonstrates high local efficacy with minimal systemic exposure, validated across multiple rare skin disease indications. With $63.6M in cash and a recent $80M raise, Palvella is well-capitalized to reach key data reado...
Neutral
GlobeNewsWire
18 days ago
Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet need
Neutral
GlobeNewsWire
19 days ago
73% of trial participants (11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall cVM-IGA) at Week 12; 67% of trial participants (10/15 participants) rated as “Much Improved” (+2) or “Very Much Improved” (+3) on the Overall cVM-IGA at Week 12
More Pieris Pharmaceuticals, Inc. News

Company Profile

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Head office United States
CEO Wesley Kaupinen
Founded 2001
Website palvellatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today